HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamide

inhibits MAP kinase kinase; structure in first source
Also Known As:
CI 1040; CI-1040; PD 184352; PD-184352; PD184352
Networked: 81 relevant articles (4 outcomes, 11 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Dent, Paul: 12 articles (04/2012 - 01/2002)
2. Grant, Steven: 12 articles (04/2012 - 01/2002)
3. Dai, Yun: 7 articles (04/2012 - 11/2002)
4. Kohno, Michiaki: 6 articles (04/2016 - 05/2003)
5. Tanimura, Susumu: 6 articles (04/2016 - 05/2003)
6. Yacoub, Adly: 5 articles (08/2011 - 11/2005)
7. Mitchell, Clint: 4 articles (08/2011 - 11/2005)
8. Rahmani, Mohamed: 4 articles (11/2009 - 01/2002)
9. Watanabe, Kazushi: 3 articles (04/2013 - 02/2010)
10. Grant, S: 3 articles (07/2011 - 07/2001)

Related Diseases

1. Neoplasms (Cancer)
2. Insulin Resistance
3. Hyperlipidemias (Hyperlipidemia)
4. Hyperglycemia
5. Breast Neoplasms (Breast Cancer)

Related Drugs and Biologics

1. Mitogen-Activated Protein Kinase Kinases (MEKs)
2. mirdametinib
3. Glucose (Dextrose)
4. Vinorelbine (Navelbine)
5. soblidotin (TZT 1027)
6. 7-hydroxystaurosporine (UCN 01)
7. 2- (2- chloro- 4- iodophenylamino)- N- cyclopropylmethoxy- 3,4- difluorobenzamide
8. MAP Kinase Kinase Kinases (MAP Kinase Kinase Kinase)
9. AZD 6244
10. Extracellular Signal-Regulated MAP Kinases (Extracellular Signal Regulated Kinases)

Related Therapies and Procedures

1. Oral Administration
2. Therapeutics
3. Nephrectomy
4. Ligation
5. Aftercare (After-Treatment)